Aurobindo Pharma announced that the United States Food and Drug Administration (USFDA) has issued Form 483 with 10 observations after the inspection of its Unit IX, Gundlamachnoor facility.

The drugmaker said that unit - IX, an intermediate facility situated at Gundlamachnoor Village, Sangareddy District, Telangana had been classified as OAI (official action indicated) on 17 May 2019 and the company had responded to the agency and carried out the required corrective actions.

The US drug regulator reinspected the facility from November 10 to 18, 2022.

Click for more articles on USFDA

At the end of the inspection, the pharmaceutical company was issued a Form 483, with 10 observations.

The observation is procedural in nature and not related to data integrity, the pharma company stated.

The pharma major added that it will respond to the USFDA, within the stipulated timeline and will work closely with the agency to address the observations at the earliest.

Aurobindo Pharma develops, manufactures, and distributes generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients.

The pharmaceutical company reported a 41.3% fall in consolidated net profit to Rs 409.45 crore on a 3.7% decline in net sales to Rs 5,673.65 in Q2 FY23 over Q2 FY22.

Shares of Aurobindo Pharma were down 1.13% to Rs 468.75 on Friday, November 18, 2022.

Other observations at firms by USFDA

USFDA issues Form 483 with 3 Observations to Alkem

USFDA issues Form 483 with 5 observations to Lupin

USFDA issues Form 483 with one Observation to Laurus Labs

USFDA issues form 483 with 17 observations to Lupin

USFDA issues form 483 with four observations to Alembic Pharma

USFDA issues 2 observations on Form 483 to Zydus Lifesciences

USFDA gives approval for Potassium-deficiency drug

Govt starts drive against misuse of Antibiotics

Bar code or QR code for 300 brands: Govt notifies these drugs under Schedule H2

USFDA gives EIR to Aurobindo Pharma for its AP facility

Maha FDA to take action against bodybuilders involved in misuse of prescription drugs

Altering the contents of formulation without changing brand names

Dr VG Somani gets another three-month extension for his post as DCGI

Govt dissolves Odisha State Pharmacy Council

First EC meeting of DCOIWA held at pink city Jaipur

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/11/19/usfda-issues-form-483-with-10-observations-to-aurobindo-pharma/